Clinical trials and research studies

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compared with placebo in rapidly terminating a seizure episode within 90seconds after IMP administration.

The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal seizure frequency.

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subjects with PGTCS.

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazolam.

This study is investigating experimental drugs TransCon IL-2 β/γ and TransCon TLR7/8 for the treatment of a

PURPOSE: This is a biological sample collection study aimed at developing an early diagnostic tool for endometrial and ovarian cancer. The investigators are studying the relationship between estrogen driven gynecological cancers, inflammation and the microbiome. Patients who have been diagnosed with endometrial cancer or undergo presurgical evaluation for suspicion of ovarian cancer who are scheduled for a hysterectomy, bilateral oophorectomy and/or salpingectomy are eligible. Control patients undergoing gynecological surgery for benign indications are also being recruited.

AOA DX is developing a blood test to detect ovarian cancer (biomarker).  The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop the ovarian cancer test.

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.